Levomepromazine Orion

Quick links

Choose a section

Quick links to important sections

Advertisements

Levomepromazine Orion

Advertisements
Advertisements

Method of action: Antipsychotic, Psycholeptics

Treatment option:

Advertisements

Overview of Levomepromazine Orion

Property Description
Active Ingredient Levomepromazine (Methotrimeprazine)
Forms Tablet, Oral Solution, Solution for Injection
Pharmacological Class Typical Antipsychotic, Neuroleptic
General Use Stabilization of acute psychological distress and pain control
Origin Synthetic organic compound (Phenothiazine derivative)

What Type of Medicine is Levomepromazine Orion?

Levomepromazine Orion is a prescription-only medication containing the single active substance Levomepromazine, which carries the Anatomical Therapeutic Chemical (ATC) code N05AA02 (Antipsychotics). It is fundamentally defined as a Typical Antipsychotic (or Neuroleptic drug), belonging to the phenothiazine chemical family. This structure dictates its powerful, multimodal action on the central nervous system, where it primarily acts as a dopaminergic antagonist to modulate nerve signaling pathways. Levomepromazine is a synthetic organic compound. The product is manufactured by Orion Corporation and its established action profile is clinically recognized for providing high-efficacy stabilization in severe mental and emotional states.

Composition, Forms, and General Use

The medication is supplied as a single active ingredient product, typically offered in the forms of an Oral Tablet, an Oral Solution, and a Solution for Injection (Ampoule), allowing administration via the oral or parenteral route. The active component is Levomepromazine, typically present as its maleate or hydrochloride salt. Beyond its primary role, Levomepromazine is particularly differentiating due to its valuable ancillary properties. The compound is used to provide combined control over mental agitation and acute pain symptoms. This dual-action capability is a key feature, making it a well-regarded choice in scenarios that require both psychological stabilization and effective mitigation of physical discomfort, as its recognized analgesic and potent antiemetic properties help control persistent nausea or vomiting simultaneously.

Advertisements

What side effects are possible with Levomepromazine Orion?

Possible Side Effects and Safety Information

Levomepromazine is associated with officially documented adverse reactions classified by frequency and system-organ class. The most frequently reported effect, classified as Very Common, is sedation or somnolence (drowsiness). This effect, along with postural hypotension (a drop in blood pressure upon standing) and asthenia (weakness/fatigue), is listed as Common and is often more pronounced early on in the course of treatment. Gastrointestinal effects, such as dry mouth (Common) and constipation (Uncommon), are also documented.


Serious Adverse Reactions

The medicine is associated with several serious reactions documented in regulatory labeling, often with a Not Known frequency. These include the potential for Neuroleptic Malignant Syndrome (NMS), a severe, idiosyncratic reaction, and the development of Tardive Dyskinesia (involuntary body movements), which is associated with long-term exposure. Cardiac safety is a significant constraint, with documented risks of QT interval prolongation and the rare occurrence of Torsades de Pointes, a serious heart rhythm abnormality. Other documented serious risks include Venous Thromboembolism (VTE), Agranulocytosis (a severe reduction in white blood cells), and Convulsions.


Population-Specific Safety Considerations

Specific safety statements apply to certain groups. Regulatory documents note that elderly patients with dementia who use this class of medicine may have an increased risk of cerebrovascular events (stroke) and an overall higher risk of death. Additionally, the risk of a drug withdrawal syndrome in neonates is noted following maternal exposure during the third trimester of pregnancy. Caution is also necessary in the context of pre-existing conditions, as the medicine is typically constrained or contraindicated in patients with a history of QT interval prolongation or Parkinson’s disease.

Advertisements

Overdose and Emergency Response

Levomepromazine overdose is defined by the official prescribing information as presenting with critical manifestations that require immediate attention. The signs of acute intoxication include simple Central Nervous System (CNS) Depression, specific motor abnormalities such as spasms and tremor, and the development of tonic and clonic convulsions.

The regulatory labeling emphasizes the potential for severe, life-threatening outcomes affecting core physiological systems. These documented outcomes include coma, respiratory depression, and severe hypotension (a form of circulatory collapse). Furthermore, toxicity may precipitate acute complications such as Neuroleptic Malignant Syndrome (NMS).

Due to the severity of these documented effects, official guidance mandates that any suspected overdose requires immediate external intervention. Individuals must contact a regional Poison Control Centre. If severe or life-threatening symptoms are present, it is required to seek immediate emergency medical attention. Management of this toxicity is exclusively symptomatic and supportive, as regulatory data confirms that no specific antidote is known to reverse the effects of the drug. The absence of an antidote underscores the need for continuous clinical monitoring and supportive care in a hospital setting.

Advertisements

Therapeutic Uses of Levomepromazine Orion

Levomepromazine Orion is commonly used to provide supportive symptomatic relief in severe clinical situations where multiple distressing symptoms are present. It generally offers supportive therapeutic benefit by addressing both acute emotional distress and accompanying physical discomfort.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used for managing major psychotic conditions like schizophrenia and acute mania. The core therapeutic domains include relief of severe behavioral and psychotic agitation, management of symptoms related to refractory nausea and vomiting, and adjunct management of severe terminal pain and accompanying distress.

The dual action supports easing the overall symptom load, offering relief that may assist patients to cope more steadily with these physically distressing manifestations. It is considered relevant in contexts involving heightened systemic burden, especially in palliative care and terminal illness, where symptoms often cluster together. Applying this medication supports maintaining a sense of stability and assists with maintaining functional stability during symptomatic phases.

Quick Fact: Relevant for Symptom Management (Severe Agitation, Intractable Nausea)

Regulatory References

  1. Summary of Product Characteristics from the Irish Health Regulator
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Levomepromazine Orion

Official regulatory documents define strict criteria for who can and cannot use Levomepromazine. Eligibility is primarily restricted by pre-existing cardiac conditions, specific comorbidities, and age.

Absolute Contraindications (Must Not Use)

Levomepromazine is contraindicated and must not be used by patients who have a known hypersensitivity to the drug or other phenothiazines. Absolute non-eligibility applies to individuals with a history of QT interval prolongation, ventricular arrhythmias, or certain cardiac rhythm disturbances like bradycardia (under 55 beats per minute) or 2nd/3rd degree heart block. Contraindication also applies if there is a risk of closed angle glaucoma, a risk of urinary retention (due to urethroprostatic disorders), or untreated hypokalaemia or other severe electrolyte imbalances.

Age-Related and Conditional Restrictions

  • Pediatric Use: The oral tablet form is contraindicated for children under 18 years of age. Use in infants is generally avoided.
  • Organ Impairment: The drug must be used with caution or avoided in patients with severe hepatic or renal impairment due to the risk of drug accumulation.
  • Geriatric Use: Use in the elderly requires caution due to increased susceptibility to effects like hypotension.
  • Pregnancy and Lactation: Levomepromazine is not recommended during pregnancy or while breastfeeding, as safety is not established and a risk to the infant cannot be excluded.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Levomepromazine primarily through two major pharmacodynamic risks: additive central nervous system (CNS) effects and the risk of ventricular rhythm disorders.

Contraindicated and High-Risk Combinations

Co-administration with several medicines is formally contraindicated due to the enhanced risk of serious ventricular arrhythmias, specifically Torsades de Pointes. These prohibited combinations include Citalopram, Escitalopram, Hydroxyzine, Piperaquine, and Domperidone. Additionally, Adrenaline (Epinephrine) must not be used in cases of neuroleptic overdose due to the risk of paradoxical hypotension.

Pharmacodynamic and Metabolic Interactions

Combining the medicine with Alcohol or other CNS depressants (such as opiates or barbiturates) results in the additive intensification of sedative effects, and co-consumption is strongly advised against. Co-use with Antihypertensives can lead to an additive hypotensive effect. A reciprocal antagonism exists with Dopaminergics (including Levodopa), and certain dopamine agonists are contraindicated. From a metabolic standpoint, Levomepromazine and its non-hydroxylated metabolites are reported to be potent inhibitors of the CYP2D6 enzyme in vitro, a potential pharmacokinetic interaction that may increase the plasma concentrations of co-administered drugs metabolized by CYP2D6.

Population and Timing Considerations

The risk of drug accumulation is noted to be increased in patients with severe hepatic and/or renal impairment. In situations where Dopaminergic agents must be discontinued to start neuroleptic treatment, the agents should be tapered off gradually.

Advertisements

Mechanism of Action

Levomepromazine functions as a multi-receptor antagonist within the central nervous system, targeting multiple monoamine neurotransmitter systems. Its principal mechanism involves the blockade of dopamine D2 receptors in mesolimbic and mesocortical pathways. This interaction results in the modulation of downstream dopaminergic signaling and corresponding alteration of neural activity.

The compound also demonstrates affinity for a variety of other receptors, including serotonin 5-HT2A, adrenergic alpha1, histamine H1, and muscarinic M1 receptors. Antagonism at these sites initiates a complex biochemical cascade that impacts numerous intracellular processes and regulatory pathways. This broad receptor binding profile dictates the full physiological consequence of the drug's action by influencing several distinct neurotransmitter systems simultaneously.

Advertisements

Dosage and Administration Information

Levomepromazine administration is officially defined by its multiple approved routes, allowing for both sustained and acute use. The drug is available in oral forms, such as tablets and solutions, primarily intended for maintenance therapy, and a solution for injection, which supports Intramuscular (IM), Intravenous (IV), and Continuous Subcutaneous (SC) routes for acute clinical needs.

Dosing is highly dependent on the use context. For oral use in psychiatric inpatients, the total initial daily dose typically ranges between 100 mg and 200 mg, which may be gradually increased up to a specified maximum of 1 g (1000 mg) daily. Outpatients generally begin with a lower daily dose of 25 mg to 50 mg. The oral dose is customarily administered in divided portions throughout the day, with a larger part often taken at bedtime to align with its use pattern.

Parenteral use for severe agitation follows a different regimen, starting typically with 12.5 mg to 25 mg, repeatable every 6 to 8 hours as necessary. Strict preparation protocols apply to these routes: IV administration requires dilution with an equal volume of normal saline immediately before use, and a similar dilution process is needed for the continuous subcutaneous infusion administered over 24 hours. Furthermore, all parenteral administration mandates a period of bed rest for five to six hours post-injection. The official guidance also specifies that treatment discontinuation must involve a gradual reduction of the dose, and a lower initial dosage is recommended for older adults.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levomepromazine Orion

Evidence for Use in Psychotic Conditions and Acute Agitation

Research exploring Levomepromazine and how it was evaluated using standardized measures of psychotic symptoms, such as in schizophrenia and acute manic episodes, primarily involves Randomized Controlled Trials (RCTs) and systematic reviews that combine the findings of multiple trials. These studies were documented and used in research exploring how symptoms change over time in adult participants, often recruited during periods of heightened symptom activity. The research monitored outcomes using standardized scales, such as the Clinical Global Impression (CGI) and the Positive and Negative Syndrome Scale (PANSS).

Systematic reviews that examined this body of evidence reported how symptoms evolved in the observed populations during the study period. The findings describe patterns observed in the studies over the defined study time intervals. The trials studied measured symptom severity scores, including comparisons to other agents. However, research highlights that evidence quality varies across studies, and many core conclusions are associated with a limited number of participants.

Evidence for Use in Palliative Symptom Control

Levomepromazine was studied for how it was observed in patients receiving palliative or end-of-life care, focusing on outcomes related to physical discomfort such as nausea, vomiting, and agitation. The evidence structure for its use in this setting is primarily based on systematic reviews of cohort studies and clinical experience reports, rather than high-level RCTs.

The research examined outcomes related to systemic or functional imbalance, such as symptom control and the requirement for additional rescue medications. While these studies contribute to the broader evidence landscape, systematic analyses have consistently documented a significant limitation: Randomized Controlled Trials are lacking for evaluating Levomepromazine's use for antiemetic purposes in adults receiving palliative care. As a result, the evidence quality for this group of indications remains low, relying on non-randomized observational data.

What is Still Uncertain about Levomepromazine Orion's Research Base

A key area of uncertainty across the research base is the need for more extensive, modern comparative studies. For psychotic conditions, the sample sizes were modest in the foundational RCTs, and comparative evidence is lacking regarding its evaluation against current standard-of-care treatments. Furthermore, there is limited information for long-term outcomes and maintenance treatment across all approved uses.

Key Studies & References

  1. Levomepromazine Orion 25 mg film-coated tablets Summary of Product Characteristics (HPRA)
  2. Nozinan Data Sheet (Levomepromazine) - Medsafe
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Levomepromazine Orion (FAQ)

Q: What is the main active ingredient in Levomepromazine Orion, and what is it primarily used for?

Levomepromazine Orion contains the active ingredient levomepromazine (also known as methotrimeprazine). It is an antipsychotic medication mainly used to treat schizophrenia and other psychotic conditions. It can also be used in the management of severe anxiety, agitation, and for its analgesic (pain-relieving) properties in palliative care, such as with certain types of cancer pain.


Q: How does Levomepromazine Orion affect the brain?

Levomepromazine is thought to work by blocking several types of receptors in the brain, including dopamine receptors (specifically D2), serotonin, histamine, and adrenergic receptors. By blocking D2 receptors, it helps to balance the levels of dopamine, which is associated with the symptoms of psychosis, thereby reducing hallucinations, delusions, and disorganized thinking. Its effect on other receptors contributes to its sedating, calming, and potential pain-relieving effects.


Q: What is the typical recommended starting dose for Levomepromazine Orion?

The typical recommended starting dose for Levomepromazine Orion varies significantly depending on the condition being treated and the individual's response. For the treatment of psychosis, the initial dose is generally low, such as 25 to 50 mg daily, usually taken in divided doses. This dose is then gradually adjusted by a healthcare provider based on the patient's specific needs, tolerance, and therapeutic response. The maximum daily dose can be up to 100-300 mg, or potentially higher in certain controlled settings, but should always be determined by a specialist.


Q: Are there any common or important side effects of Levomepromazine Orion that I should be aware of?

Yes, Levomepromazine Orion can cause several common and important side effects, often due to its wide range of effects on different receptors in the body.

Common side effects include:

  • Sedation or drowsiness
  • Orthostatic hypotension (a drop in blood pressure when standing, which can cause dizziness)
  • Dry mouth
  • Constipation
  • Weight gain

More serious or important potential side effects include:

  • Extrapyramidal symptoms (EPS): Movement disorders like tremors, muscle stiffness, or restlessness.
  • Neuroleptic Malignant Syndrome (NMS): A rare but potentially life-threatening reaction characterized by high fever, severe muscle rigidity, altered mental status, and irregular pulse or blood pressure.
  • Prolongation of the QT interval: An electrical change in the heart that may be observed on an ECG and carries a risk of serious heart rhythm disturbances. Regular monitoring of the heart is often required.

Q: Can Levomepromazine Orion be stopped abruptly, or does it need to be tapered off?

Levomepromazine Orion should not be stopped abruptly. Suddenly discontinuing the medication, especially after prolonged use, can lead to withdrawal symptoms and the re-emergence or worsening of the original psychiatric symptoms. Withdrawal symptoms can include nausea, vomiting, sweating, tremor, and difficulty sleeping.

If the decision is made to stop treatment, the dose should be gradually tapered (reduced slowly) over a period of time, as directed by a healthcare professional. This process helps the body adjust and minimizes the risk of severe side effects and relapse.


Q: Can Levomepromazine Orion interact with other medications, and if so, which ones are important to note?

Yes, Levomepromazine Orion has a high potential for drug interactions due to its effects on various receptors and its metabolism in the liver. It's crucial to inform a healthcare provider about all other medications, supplements, and herbal products being taken. Important interactions to note include:

  • Other Central Nervous System (CNS) depressants: Combining it with alcohol, benzodiazepines (e.g., diazepam), opioids, or other sedating drugs can significantly increase the risk of severe drowsiness, respiratory depression, and sedation.
  • Drugs that prolong the QT interval: Combining with other medications that affect the heart's electrical activity (e.g., certain antiarrhythmics, antibiotics, or other antipsychotics) can increase the risk of serious heart rhythm problems. This requires careful ECG monitoring.
  • Antihypertensive drugs: Levomepromazine's blood pressure-lowering effect (orthostatic hypotension) can be magnified when taken with medications used to treat high blood pressure, increasing the risk of dizziness and fainting.
Advertisements

How should Levomepromazine Orion be stored and disposed of?

How to Store and Dispose of Levomepromazine Orion?

Official Storage Requirements

Levomepromazine tablets generally do not require special temperature conditions for storage, but it is a mandatory regulatory requirement to protect the medication from light. The product must be kept in its original package to ensure this protection and stability. The solution for injection typically requires storage below 25 C and should be used immediately after opening.

Storage Constraint Requirement
Temperature No special conditions (tablets); Store below 25 C (injection)
Protection Keep in the original package to protect from light
Child Safety Must be kept out of the sight and reach of children

Official Disposal Instructions

Disposal of any unused or expired Levomepromazine must be performed in accordance with local requirements for pharmaceutical waste. To comply with environmental standards, the official guidance strictly states not to throw the medicine away via wastewater or household trash. Patients are instructed to return all unused medication to a pharmacist for responsible disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levomepromazine Orion found in:

A-Z Index: